4DMedical Limited
ASX: 4DX
Heavy losses and funding reliance persist, while FDA uncertainty and overbought RSI flag correction risk.
(Source: TradingView) 3-Month Performance Profile of 4DX on a DTF compared to S&P/ASX 200 (XJO).
In FY2025, the company posted a net loss of $30.07 million, with operating expenditure at $48.2 million far outweighing revenue of just $5.9 million, reinforcing
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
